The Food and Drug Administration approved a new use for San Francisco-based Genentech's drug Lucentis.
Here are four things to know.
1. Lucentis can now be used to treat myopic choroidal neovascularization, a complication of severe nearsightedness that can lead to vision loss or blindness.
2. The drug earned priority review status for this use from the FDA in October. The priority review process, which expedites the review of a drug application to about six months after filing, was created to decrease the time it takes to put new medicines on the market.
3. Genentech — a member of Basel, Switzerland-based Roche Group — will maintain all commercial rights to Lucentis in the U.S., while Roche will hold commercial rights abroad.
4. This is the fifth FDA-approved indication for Lucentis since the drug first launched in 2006.
More articles on supply chain:
6 must-reads for supply chain leaders this week
10 medical device trends for 2017
Director of supply chain named one of best jobs in America by CNNMoney